Nivolumab 40mg and 100mg Injection — PD-1 Checkpoint Inhibitor for Multiple Advanced Cancers
Description:
Nivolumab 40mg and 100mg Injection — PD-1 Checkpoint Inhibitor for Multiple Advanced Cancers
Tishtha® (Nivolumab) — PD-1 Checkpoint Inhibitor Immunotherapy for Advanced Cancers
A Sourcing Guide for Hospitals and Oncology Centres
Tishtha® (Nivolumab) is a fully human monoclonal antibody indicated, according to the manufacturer’s approved prescribing information, for the treatment of multiple advanced cancers including non-small cell lung cancer, melanoma, renal cell carcinoma, and head and neck cancer, among other approved indications. As with all immuno-oncology therapies, the decision to prescribe Tishtha, including patient selection, biomarker testing where applicable, and treatment regimen, rests entirely with the treating oncologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Tishtha (Nivolumab), in both 40mg and 100mg strengths, to hospitals, oncology centres, and pharmacies across India.
Tishtha contains Nivolumab, a fully human IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor, a key immune checkpoint protein.
PD-1 Checkpoint Signalling and Cancer Immune Evasion:
According to published immuno-oncology literature, T-cells express the PD-1 receptor as part of a normal regulatory mechanism that prevents excessive immune activation and autoimmunity. Many tumours exploit this pathway by expressing PD-L1, the ligand for PD-1, on their cell surface. When PD-L1 on a tumour cell binds PD-1 on a T-cell, it delivers an inhibitory signal that suppresses T-cell activity, allowing the tumour to evade immune-mediated destruction — a mechanism often referred to as immune checkpoint-mediated immune evasion.
Nivolumab’s Mechanism: By binding to the PD-1 receptor on T-cells, Nivolumab blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, according to the manufacturer’s prescribing information. This releases the inhibitory brake on T-cell activity, restoring the immune system’s capacity to recognise and attack tumour cells, rather than acting directly on the tumour itself as conventional chemotherapy does.
Full prescribing information is available at the FDA label for Nivolumab, with additional background on immune checkpoint inhibition available via the National Cancer Institute.
CheckMate 017 and CheckMate 057 Trials (Nivolumab in Non-Small Cell Lung Cancer)
Published in the New England Journal of Medicine (2015), these pivotal trials evaluated Nivolumab against docetaxel chemotherapy in previously treated advanced NSCLC, across squamous and non-squamous histology respectively. Both trials demonstrated significantly improved overall survival with Nivolumab compared to chemotherapy, establishing its role in second-line NSCLC treatment.
CheckMate 067 Trial (Nivolumab in Advanced Melanoma)
Published in the New England Journal of Medicine (2015), CheckMate 067 evaluated Nivolumab alone and in combination with Ipilimumab against Ipilimumab alone in previously untreated advanced melanoma, demonstrating significantly improved progression-free survival with Nivolumab-containing regimens, with long-term follow-up data supporting durable survival benefit in a meaningful proportion of patients.
CheckMate 025 Trial (Nivolumab in Renal Cell Carcinoma)
Published in the New England Journal of Medicine (2015), this trial demonstrated significantly improved overall survival with Nivolumab compared to everolimus in patients with previously treated advanced renal cell carcinoma.
CheckMate 141 Trial (Nivolumab in Head and Neck Cancer)
Published in the New England Journal of Medicine (2016), CheckMate 141 demonstrated improved overall survival with Nivolumab compared to investigator’s choice chemotherapy in patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
For broader clinical guidance on immune checkpoint inhibitor use across tumour types, the American Society of Clinical Oncology (ASCO) publishes ongoing treatment guidelines for oncologists.
Tishtha is available as:
| Presentation | Strength |
|---|---|
| Tishtha 40mg Injection | 40mg per vial |
| Tishtha 100mg Injection | 100mg per vial |
Dosing regimen, including whether weight-based or flat dosing is used, and treatment interval, is determined by the prescribing oncologist according to the specific approved indication and the current prescribing information.
According to its approved prescribing information, Nivolumab carries multiple oncology indications, generally including:
The specific indication, line of therapy, and any required biomarker testing (such as PD-L1 expression, where applicable to a given indication) should always be confirmed against the most current approved prescribing information for the relevant indication.
For detailed indication information refer to MedlinePlus Nivolumab.
Broad Multi-Tumour Approval Base
Nivolumab’s approval across multiple solid tumour types reflects the broad relevance of PD-1 checkpoint blockade across cancers that exploit this specific immune evasion mechanism.
Demonstrated Overall Survival Benefit Across Several Tumour Types
Landmark CheckMate trials established significant overall survival improvements compared to prior standards of care in lung cancer, melanoma, renal cell carcinoma, and head and neck cancer.
Durable Responses in a Subset of Patients
Long-term follow-up from trials such as CheckMate 067 has demonstrated durable survival benefit in a meaningful proportion of treated patients, a distinguishing feature of immune checkpoint inhibitor therapy compared to some conventional treatments.
Combination Therapy Options
Nivolumab has been studied and approved in combination with other agents, including other checkpoint inhibitors, in certain indications, providing oncologists with combination treatment strategies per the approved label.
Dosing of Tishtha is determined by the prescribing oncologist according to the approved label for the specific indication being treated. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating oncologist.
Tishtha is prescribed by oncologists for:
Tishtha is prescribed by oncologists managing a range of solid tumour malignancies. A.K. Pharma supplies Tishtha to hospitals and oncology centres across Delhi and India.
Common side effects reported in clinical trials include fatigue, rash, diarrhoea, nausea, and musculoskeletal pain.
Serious side effects include:
Immune-Mediated Adverse Reactions: As a class effect of checkpoint inhibitors, Nivolumab can cause immune-mediated inflammation affecting various organs, including pneumonitis, colitis, hepatitis, endocrinopathies (thyroid, adrenal, pituitary), nephritis, and dermatological reactions. These require prompt recognition and management per the approved prescribing information, which may include corticosteroid therapy and treatment interruption or discontinuation depending on severity.
Infusion-Related Reactions: Reported with intravenous administration; monitoring during and after infusion is recommended per standard oncology infusion protocols.
Severe Skin Reactions: Including rare but serious dermatological reactions requiring prompt evaluation.
Full side effect information is available at FDA Nivolumab Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all oncology biologics including Tishtha under manufacturer-recommended cold chain conditions ensuring product integrity for every supply.
Tishtha (Nivolumab) is the Indian brand of Nivolumab, the same active ingredient as the internationally recognised Opdivo (Bristol Myers Squibb), providing accessible pricing for Indian patients requiring PD-1 checkpoint inhibitor therapy. A.K. Pharma supplies only genuine Tishtha sourced from authorised distributors.
Q. What is Tishtha used for?
Tishtha (Nivolumab) is used to treat multiple advanced cancers, including non-small cell lung cancer, melanoma, renal cell carcinoma, and head and neck cancer, among other approved indications, per the current prescribing information.
Q. What is the generic name of Tishtha?
The generic name of Tishtha is Nivolumab, a PD-1 checkpoint inhibitor and the Indian brand equivalent of the internationally recognised Opdivo.
Q. How does Tishtha work as an immunotherapy?
Tishtha blocks the PD-1 receptor on T-cells, preventing tumour cells from using the PD-1/PD-L1 pathway to suppress immune attack, thereby restoring the immune system’s ability to recognise and attack cancer cells.
Q. What is the difference between Tishtha 40mg and 100mg?
The two strengths allow for weight-based or flat-dose regimens to be prepared according to the approved dosing schedule for the specific cancer type being treated, as determined by the prescribing oncologist.
Q. Is Tishtha available in India?
Tishtha can be supplied to hospitals and oncology centres across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Tishtha in India?
Tishtha price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Tishtha from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Tishtha in bulk?
Yes. A.K. Pharma supplies Tishtha in bulk to hospitals and oncology centres across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
